Rapid eye movement sleep behavior disorder (RBD) …

Stuart J McCarter MD

Sleep Disorders

Updated 09.01.2022
Released 09.09.1993
Expires For CME 09.01.2025

Rapid eye movement sleep behavior disorder

Author: Stuart J McCarter MD

See Contributor Disclosures

Editor: Michael J Howell MD

Rapid eye movement sleep behavior disorder

In This Article

Quick Link

Introduction

Overview

In this article, the author reviews and updates REM sleep behavior disorder (RBD), characterized by REM sleep without atonia (RSWA) with potentially injurious dream enactment. The RSWA of RBD is due to dysfunction of REM-related circuitry in the pons and medulla and often predates the development of Parkinson disease or other disorders of alpha-synuclein pathology. Other pathogenic processes include orexin deficiency, pontomedullary lesions, limbic dysfunction, hypothalamic dysfunction, as well as toxic effects from serotonergic antidepressant medications. Management of RBD is focused on decreasing sleep-related injury through changes in the sleeping environment and, if necessary, bedtime melatonin or clonazepam. As RBD is a prodromal syndrome of alpha-synuclein degeneration, it is an ideal target for disease modifying agents.

Key points

	• Under nonpathological circumstances, REM sleep is characterized by an activated brain state in combination with skeletal muscle paralysis. This paradox, wake-like brain activity combined with flaccid motor function, prevents the enactment of dream activity. In REM sleep behavior disorder (RBD), REM sleep atonia is lost and patients act out dream mentation.
	• The majority of patients with spontaneously occurring RBD (isolated RBD, iRBD) will eventually demonstrate signs and symptoms of neurodegenerative disorders, most commonly one of the synucleinopathies (Parkinson disease, dementia with Lewy bodies, and multiple system atrophy), often after a prolonged interval lasting decades. RBD in the setting of other neurodegenerative diseases such as Alzheimer disease suggests co-mingling synucleinopathy.
	• iRBD patients have an approximately 6% risk per year after RBD diagnosis of being diagnosed with Parkinson disease, dementia with Lewy bodies, or multiple system atrophy.
	• Parkinson disease patients with RBD have more rapid disease progression, more cognitive impairment, and more postural instability and falls, with an overall worse prognosis compared with Parkinson disease patients without RBD.
	• Other causes of RBD include pontomedullary lesions, such as those from vascular injuries, mass lesion, or demyelinating disease. Commonly prescribed antidepressant medications, particularly selective serotonin reuptake inhibitors, result in RBD through uncertain mechanisms. Patients with narcolepsy due to dysfunction in the orexin hypothalamic circuit, which stabilizes sleep states, may also demonstrate RBD, but it may be less likely to develop a neurodegenerative disease than iRBD. By failing to stabilize REM sleep from wakefulness, orexin pathology results in cortical activation, but without REM sleep atonia.
	• RBD management options include prioritizing bedroom safety in addition to bedtime administrations of low-dose (0.25 to 1.0 mg) clonazepam or high-dose (6 to 15 mg) melatonin. For patients with medication refractory disease, a customized bed alarm may help prevent sleep-related injury.

Historical note and terminology

In 1817, James Parkinson wrote a monograph titled, “An Essay on the Shaking Palsy” (118). This first comprehensive description of the disorder described frequently disrupted sleep. Parkinson hinted at a disorder of agitated dream enactment emerging from sleep.

“His (Case VI) attendants observed, that of late the trembling would sometimes begin in his sleep, and increase until it awakened him: when he always was in a state of agitation and alarm.”

“…when exhausted nature seizes a small portion of sleep, the motion becomes so violent as not only to shake the bed-hangings, but even the floor and sashes of the room.”

After the discovery of REM sleep in the 20th century, investigations explored the brainstem mechanisms of REM skeletal muscle paralysis. In 1965, experimental lesions of pontine regions adjacent to the locus coeruleus in cats caused absence of the expected REM sleep atonia and prominent motor behaviors during REM sleep (74).

Subsequently, in 1982, Dr. Carlos Schenck and Dr. Mark Mahowald evaluated a 68-year-old man with a history of violent dream enactment behavior. A subsequent polysomnogram demonstrated REM sleep without atonia along with vigorous dream enactment behavior. In 1986, Schenck and Mahowald published a series of patients with violent dream enactment behavior with a paucity of REM atonia and named the condition “REM sleep behavior disorder” (141). In 10 years, 38% of these original RBD patients had developed a parkinsonian syndrome, and within 25 years, the prevalence had risen to 81% (144).

Historically, RBD occurring in the absence of a neurodegenerative disease, structural lesion, or other known causative etiology of RBD has been termed “idiopathic” RBD. However, as “idiopathic” RBD is now widely accepted as the initial manifestation of an alpha-synucleinopathy neurodegenerative disease in the vast majority of cases, the term “isolated” RBD is preferable to that of idiopathic as idiopathic implies a lack of understanding of the underlying cause. As such, throughout the review, iRBD refers to isolated RBD (60).

Clinical manifestations

Presentation and course

	• REM sleep behavior disorder should be suspected in patients who have repeated episodes of excessive seemingly purposeful or semipurposeful motor activity at night that can mirror dream content, oftentimes with associated injuries to the patient or bedpartner.
	• Bed partner input on nocturnal behaviors is helpful as patients themselves are often unaware of their nocturnal behaviors.
	• Isolated RBD patients often demonstrate subtle motor impairment on tasks testing fine motor skills.
	• Symptoms of autonomic impairment in isolated RBD include constipation, erectile dysfunction, and orthostatic intolerance.
	• Visuospatial and executive dysfunction are common in isolated RBD, mirroring the impairments found in patients with dementia with Lewy bodies.
	• The presence of comorbid RBD in patients with Parkinson disease portends a worse prognosis with more cognitive impairment, more severe motor symptoms, worse quality of life, increased postural instability, and gait dysfunction compared with Parkinson disease patients without RBD.

Table 1. REM Sleep Behavior Disorder Criteria (ICSD-3)

	A. Repeated episodes of sleep-related vocalization and/or complex motor behaviors.
	B. These behaviors are documented by polysomnography to occur during REM sleep or, based on clinical history of dream enactment, are presumed to occur during REM sleep.
	C. Polysomnographic recording demonstrates REM sleep without atonia (RSWA).
	D. The disturbance is not better explained by another sleep disorder, mental disorder, medication, or substance use.

RBD presents with a complaint of dream enactment behavior (see Table 1 for ICSD-3 criteria) or sleep-related injury. The spectrum of dream enactment behavior varies from small hand movements to leaping out of bed. The frequency of episodes ranges from once every few months to multiple nightly episodes. Often, there is a prolonged prodromal period lasting years with progressively more prominent dream enactment behavior. Some patients adopt extraordinary measures to prevent sleep-related injury: they may place obstacles to hinder exiting the bed or sleep in a room devoid of furniture. Prolonged diagnostic delay is common, and some families deal with these behaviors for decades prior to seeking medical attention (66).

RBD movements appear purposeful, such as throwing a ball or flailing to protect oneself (02). These movements, with their complex and repetitive nature, are often distinguished from other nocturnal behaviors on polysomnography based on appearance alone. Unlike NREM parasomnias, the duration of behaviors in RBD is brief, and on awakening from an episode, there is usually a rapid return to alertness and orientation. These characteristics are not unexpected as unlike NREM sleep, a low arousal threshold characterizes REM.

The reported motor activity usually correlates with remembered dream mentation, leading to the patient’s (or the patient’s bedpartner) complaint of "acting out dreams." Interestingly, unlike normal dream mentation, which is often forgotten by dreamers within a few minutes of awakening, RBD patients often recall dreams with striking clarity for weeks or years (66). Importantly, RBD patients do not have more violent dreams than normal individuals; instead, they merely act them out. Further, during the daytime, they are not more aggressive, nor do they suffer from personality disturbances (93).

In RBD, sleep-related vocalizations are typically loud and aggressive (expletives are not uncommon). This is most often discordant from waking personality. Further, RBD vocalizations need to be distinguished from sleep talking, which is common (during both NREM and REM), more typical of daytime conversation, and does not, in itself, represent pathology.

Due to its association with REM sleep, it is not unexpected that dream enactment behavior appears more often during the later periods of the sleep period. Even so, events in the latter half of the night REM sleep are more likely to demonstrate violent-aggressive features. RBD, like REM sleep, rarely occurs during daytime naps, with a significant exception for cases associated with narcolepsy (66).

In the absence of injury, most RBD patients attribute only minimal daytime consequences, if any, to their nocturnal behaviors. One study noted that 70% of patients reported good sleep quality. However, this is in contrast to the patients’ bed partners; 44% of patients were unaware of dream enactment until their bed partners told them (42).

Ancillary clinical features of RBD. Patients with RBD demonstrate various features of Parkinson disease and other Lewy body diseases (see Etiology section). Investigations have illuminated these motor, cognitive, and autonomic impairments.

Motor testing reveals that patients with RBD demonstrate abnormalities often imperceptible on a general clinical exam. These are notable approximately 5 to 7 years prior to the diagnosis of Parkinson disease, with subtle abnormalities on the alternate tap test being the first motor abnormality to appear as early as 13 years prior to Parkinson diagnosis (39). It should be noted that typical cardinal features of Parkinson disease, such as rigidity and tremor, typically appear 2 to 3 years prior to Parkinson disease diagnosis in patients with iRBD (39).

Patients with RBD have cognitive impairments, in particular visuospatial deficits and executive dysfunction, which correlate with mild predominantly occipital hypometabolism on FDG-PET scans (22). In particular, progressive abnormalities have been found in visual perception, visuospatial learning, facial expression recognition, and color identification (66; 125). Other investigations have revealed impairments in attention and executive function, with executive dysfunction and visuospatial impairment predicting more rapid phenoconversion (15; 125a; 156). Further, the presence of pareidolic responses in patients with isolated RBD correlates with underlying cognitive impairment and may predict future development of clinically overt Lewy body disease (139). Consistent with these findings, in vivo PET imaging of acetylcholinesterase activity has shown reduced superior temporal cortex, occipital cortex, cingulate cortex, and dorsolateral prefrontal cortex cholinergic activity (53).

The cognitive deficits among RBD patients with dementia are more similar to dementia with Lewy bodies (DLB) than to Alzheimer disease (15; 121). Further, among patients with mild cognitive impairment who were later proven to have dementia with Lewy bodies, nearly all had symptoms of RBD (15). Also, the presence of RBD symptoms in patients with dementia predicts dementia with Lewy bodies on postmortem examination (108). The presence of RBD in a patient with cognitive impairment consistent with Alzheimer disease dementia is highly suggestive of underlying comorbid synuclein pathology (17).

Prior to the onset of Parkinson disease, RBD subjects demonstrate mild postural and gait abnormalities. While attempting to stand motionless, patients with RBD have postural instability when distracted (25). Then, during gait initiation, RBD patients show a pattern of abnormal force generation consistent with FOG (161). Subsequently, while ambulating, there is a measurable decline in velocity and cadence, with an increase in stride and swing variability of limb movements in RBD (104).

In general, Parkinson disease patients with RBD appear to have a more malignant and aggressive disease characterized by a higher Hoehn and Yahr stage, more cognitive impairment, worse quality of life, increased postural instability, and gait dysfunction compared with Parkinson disease patients without RBD (24; 66; 125c; 136). Neuroimaging studies of Parkinson disease patients with RBD show more widespread cortical and subcortical atrophy than Parkinson disease patients without RBD (133). Further, Parkinson disease patients with RBD appear to be more likely to have freezing of gait (FOG) and a higher frequency of falls compared with Parkinson patients without RBD (58). Studies have suggested a Parkinson disease classification scheme of mild-motor predominant, diffuse malignant, and intermediate phenotypes (40). Patients with RBD fall into the diffuse malignant or intermediate phenotypes, which are associated with more rapid disease progression and earlier mortality compared with mild-motor predominant Parkinson disease (32).

Comorbid hyposmia is frequently noted in cases of spontaneous RBD and is likely the first symptom (apart from RBD) suggestive of neurodegeneration, presenting greater than 20 years prior to phenoconversion (40). These impairments in olfaction are likely representative of evolving Lewy body disease and not multiple system atrophy, in which olfaction remains normal (132).

Autonomic dysfunction as measured by heart rate variability, cardiac scintigraphy, and orthostatic responses is frequently present in RBD patients, with some studies showing that abnormalities in cardiac scintigraphy precede changes in DaTscan (50; 148; 11; 72).

Prior to the onset of motor features, constipation is the most prominent autonomic symptom among patients with RBD and suggests early alpha-synuclein degeneration of enteric neurons, presenting approximately 10 years prior to phenoconversion (41; 39). Additionally, alpha synuclein depositions in the enteric nervous system have been found in patients with Parkinson disease and Parkinson disease with RBD with slower colonic transit time, suggesting the presence of RBD indicates the manifestation of a widespread synucleinopathy (82). This has been confirmed by the presence of phosphorylated alpha-synuclein in skin biopsies of patients with iRBD and an association with more severe autonomic dysfunction on standardized autonomic testing (105).

One notable exception to the link between RBD and Parkinson disease are patients with familial cases of Parkinson disease. The most studied familial cases involve patients with the LRRK-2 mutation, who are less likely to have RBD (122). On the other hand, mutations in glucocerebrosidase (GBA) are associated with both Parkinson disease and RBD, with the presence of GBA mutations in patients with iRBD, suggesting a more rapid rate of phenoconversion (62).

Prognosis and complications

Sleep-related injuries may result from behaviors such as punching, kicking, or leaping out of bed, with greater than 50% of patients or bedpartners reporting injury (99). Examples of sleep-related injury include subdural hematoma, shoulder dislocation, cervical fracture, as well as lacerations severing arteries, tendons, and nerves. As bed partners are frequently the target of violent dream enactment, RBD may have forensic implications, with patients wrongly in the criminal justice system (66).

Initially, most patients with RBD do well with environmental changes and pharmacotherapy. The most commonly prescribed medications include bedtime oral clonazepam or melatonin (15; 81; 66). However, the long-term efficacy and safety of these agents in the setting of progressive dementing illnesses are uncertain. One follow-up study of clonazepam demonstrated that half of all patients would ultimately either decrease the nighttime dose due to side effects or discontinue the medication (03). RBD has also been reported to be an independent predictor of mortality in Parkinson disease and typically is associated with a poor prognosis in Parkinson disease (164). Conversely, patients with RBD have increased mortality when compared with the general population only if they develop a clinical neurodegenerative disease (170).

Ultimately a patient’s prognosis depends on the underlying pathological process. Both toxic RBD and dream enactment behavior due to sleep apnea are typically resolved by eliminating the offending agent or treating the sleep-disordered breathing, respectively (66). Among neurodegenerative cases, the interval between the onset of RBD and disabling neurologic symptoms varies from months to decades.

Predicting the rate of phenoconversion. Numerous ancillary clinical features can help predict how rapid a patient with RBD will develop a parkinsonian disorder. Patients who are older and have family history of dementia are more likely to convert within 4 years (125a). In addition, subtle motor or cognitive dysfunction, orthostatic hypotension, constipation, hyposmia, impaired color vision, and nonuse of antidepressants predicts more rapid conversion (91; 125b; 09; 38). Stratification with these markers increases risk of conversion by 200% (125b). RBD patients with errors in the trail making test (part B) predicted the development of dementia, whereas verbal fluency (semantic) and verbal episodic learning tests appear best to monitor changes in cognition of patients with RBD over time (92).

Decreased dopamine uptake (as measured by DAT-SPECT scan) in the putamen is associated with increased short-term risk of phenoconversion to Parkinson disease, suggesting serial DATSCANs may be useful in monitoring disease progression in patients with isolated RBD (83). Specifically, quantitative analysis of DAT tracer uptake in the putamen appears to be a robust predictor of short-term phenoconversion, with additional variables such as age greater than 70 at the time of DATSCAN and the presence of constipation increasing the risk even further (06). [18 F]fluorodeoxyglucose-PET (FDG-PET) scans of the brain with a Parkinson disease-related brain pattern at isolated RBD diagnosis also appear to predict more rapid phenoconversion, with serial FDG-PET scans showing a higher frequency or intensity of the Parkinson disease-related brain pattern over time (79).

CSF alpha-synuclein positivity as measured by real-time quaking-induced conversion (RT-QuIC) has been shown to be associated with a higher risk of phenoconversion compared with patients with isolated RBD who were RT-QuIC negative at diagnosis (70). It should be noted that although the risk and rate of phenoconversion in the typical RBD patient (ie, older than 65 years old at diagnosis/symptom onset and male gender), the significance of RBD in patients younger than 50, associated with antidepressant use or autoimmune disease, is much less well known. Prospective data in patients with longstanding RBD (ie, disease free 10 years after RBD diagnosis) suggest that these patients still have similar prodromal biomarkers of neurodegeneration or evidence of subclinical Parkinson disease similar to patients who developed neurodegenerative disease within 4 years of RBD diagnosis (71; 165).

Overall, the ideal method of predicting phenoconversion remains controversial. From a practical standpoint, the presence of older age at diagnosis in combination with more abnormal biomarkers (abnormal DATSCAN, FDG-PET scan, anosmia, constipation, motor impairment, autonomic dysfunction, mild cognitive impairment, increased REM sleep without atonia) likely confers a higher risk of more imminent phenoconversion.

Clinical vignette

A 71-year-old retired police officer returned to the sleep center 10 years after being diagnosed with obstructive sleep apnea and treated with continuous positive airway pressure (CPAP). The patient indicated that despite excellent compliance over the last decade, he suspected that he no longer had obstructive sleep apnea. In particular, his CPAP machine broke 6 months prior, and he had been asymptomatic (no daytime sleepiness) despite a lack of treatment. Further, his wife stated that he no longer snored, nor did he appear to have labored breathing. His weight had not significantly changed.

Interestingly, the patient’s spouse also indicated that he had developed a 2-year history of dream enacting behaviors. These behaviors had become progressively more disruptive, initially characterized by loud vocalization and random twitches during sleep, then progressing to yelling, swearing, and flailing. The vocalizations suggested that the patient was dreaming of his police work. One event wherein he jumped out of bed resulted in fractures of two lumbar vertebrae. If awakened following these episodes, he was immediately awake, alert, and oriented and recalled his dream mentation.

Polysomnography revealed prominent tonic and phasic muscle activity during REM sleep associated with vocalization and kicking motions. Despite spending the entire night supine, the patient did not have sleep disordered breathing.

The patient’s dream enactment behavior was initially treated with bedtime oral clonazepam. However, the patient was unable to tolerate residual morning sleep inertia and switched to high-dose melatonin. Melatonin at 12 mg eliminated the majority of dream enactment behaviors; however, he still left the bed during a dream approximately once a week. Both the patient and spouse were concerned about possible sleep-related injury.

The patient was given a customized bed alarm, with voice recording unit. Subsequently, when the patient sat upright during a dream the pressure sensing pad triggered his wife’s admonition from the bedside speaker, “Pat, you’re having a dream go back to sleep.” At 6 months, he had not had any further sleep-related injuries.

Biological basis

Etiology and pathogenesis

	• Nearly all patients with isolated RBD eventually develop an alpha-synucleinopathy (Parkinson disease, dementia with Lewy bodies and multiple system atrophy) over time.
	• Symptoms of RBD in non-synucleinopathies suggests comingling synucleinopathy.
	• Structural lesions to the brainstem, specifically the dorsal pons and medulla, can cause RBD that is not associated with a progressive neurodegenerative disease.
	• RBD frequently occurs in patients with narcolepsy type 1 and can be seen a variety of autoimmune encephalopathies.
	• A variety of medications are known to provoke RBD, most commonly selective serotonin reuptake inhibitors, and are thought to unmask a latent predisposition to develop RBD rather than causing RBD per se.

RBD represents the final common pathway of several diverse pathologies, all of which result in a failure to inhibit central motor pattern generators and spinal motoneurons. These pathologies manifest in a loss of behavioral control during REM sleep and the enactment of dream mentation (15). However, it has been postulated that dream enactment behaviors in RBD may occur secondary to a “bottom up” process rather than a “top down” (14). In this proposed model, loss of REM muscle atonia due to brainstem dysfunction results in dream enactment behavior that is interpreted into dreams (rather than dreaming first and acting out what one dreams). This is based on studies of brainstem stimulation that can produce defensive and aggressive behaviors in rats and monkeys that are similar to those seen in RBD. Therefore, sensory feedback from moving limbs may influence dream mentation.

The suppression of motor activity during normal REM sleep is the cumulative result of multiple, currently poorly understood pathways that ultimately terminate on spinal motor neurons, most notably via the magnocellular reticular formation in the medulla. Multiple areas of the brainstem may influence muscle tone during REM sleep. These include pontine REM-on (precoeruleus and sublateral dorsal) and REM-off (ventral lateral portion of the periaqueductal grey matter and lateral pontine tegmentum) nuclei (15). Various other brainstem structures mediate REM paralysis at least partially through GABA and glycine inhibition of motor neurons (67). Genetic inactivation of the rat sublateral dorsal nucleus (analogous to the human locus subcoeruleus) causes REM sleep without atonia but does not impact cortical features of REM sleep (160). Dysfunction in these REM modulating structures as well as their related neurotransmitters and pathways can result in REM sleep without atonia (15; 75; 67).

With the exception of cases caused by a focal lesion, such as a stroke, it is difficult to localize RBD pathology. However, investigations are beginning to focus on the coeruleus complex. Evaluating for neuromelanin with 3T MRI, changes were seen in the coeruleus area among patients with RBD and Parkinson disease as well as RBD alone (35). A neuroimaging study utilizing 7T MRI to assess brainstem connectivity with tractography in patients with iRBD has shown decreased excitatory connectivity between the locus coeruleus/subcoeruleus complex and ventromedial medullary nuclei known to be integral for REM sleep atonia generation, mirroring what has been shown in animal studies of RBD (51).

Synuclein neurodegenerative etiologies. The majority of spontaneously developing RBD cases are related to Lewy body CNS pathologies. These conditions include Parkinson disease, multiple system atrophy, dementia with Lewy bodies, and pure autonomic failure. Patients with these disorders have increased alpha-synuclein oligomers in the CSF, a marker of neurodegeneration, and demonstrate pathological alpha-synuclein deposition in the CNS on postmortem examination. These findings have also been described in RBD (66; 68). Further, some patients with isolated RBD demonstrate synuclein deposition in the olfactory mucosa, skin, and enteric plexus. The brainstem nuclei that control REM sleep (see Pathogenesis and pathophysiology section) are often involved early in the natural history of synucleinopathies (15).

The interval between the onset of RBD and diagnosis of Parkinson disease or related disorders can vary from months to decades. The largest multicenter study of greater than 1000 patients with iRBD reported a 6.3% per year risk of phenoconversion, with 73.5% of patients phenoconverting within 12 years from RBD diagnosis (130). Among the rare cases of apparently persistent isolated RBD, biomarkers still demonstrate impending neurodegeneration (165). Further, the finding of diffuse Lewy body disease on postmortem evaluation in otherwise asymptomatic patients with RBD suggests that in the setting of very slow disease progression, dream enactment may be the sole clinical manifestation of alpha-synuclein pathology.

By the time motor abnormalities develop in patients with Parkinson disease, the vast majority (up to 90%) of dopaminergic neurons in the substantial nigra are irreversibly dysfunctional (80). As RBD is a prodromal syndrome of Parkinson disease, neuroimaging and transcranial magnetic stimulation studies have demonstrated coincident and progressive dopaminergic, cholinergic, and other related parkinsonian abnormalities (109; 61; 133; 31).

Forebrain pathologies are also implicated in the failure to suppress motor activity in RBD, presumably by unleashing central pattern generators, functional groups of neurons that give rise to stereotyped patterns of behavior such as startling, punching, or jumping. This is the purported pathway by which clonazepam suppresses dream enactment behavior as clonazepam does not promote tonic REM sleep atonia on polysomnography. Dream enactment behaviors bypass the basal ganglia in contrast to wakeful movements (94; 57). This helps explain why RBD actions are often not parkinsonian, in contrast to the bradykinetic movements these Parkinson disease patients may have during wakeful hours.

Non-synuclein neurodegenerative etiologies. RBD has been associated with other neurodegenerative pathologies. RBD has been reported in cases of Alzheimer disease, tauopathy-related parkinsonian syndromes (progressive supranuclear palsy, corticobasal degeneration, and Guadaloupean parkinsonism), and TDP-43-opathies (frontotemporal dementia, amyotrophic lateral sclerosis), although the presence of RBD in these cases is most likely related to co-mingling alpha-synucleinopathy pathology. However, studies of RSWA comparing patients with synucleinopathy and non-synucleinopathy diagnoses have shown similar levels of RSWA in non-synucleinopathies compared with non-RBD control patients, which brings into question whether or not RBD reported in non-synucleinopathies could represent other diagnoses (periodic limb movement disorder, non-REM parasomnia, obstructive sleep apnea) (97; 102).

Also, RBD has been noted in some trinucleotide and tetranucleotide repeat disorders, including spinal cerebellar ataxia types 2 (SCA2), 3 (SCA3), 31 (SCA31), Huntington disease, and myotonic dystrophy type 2. In addition, RBD has been reported to occur in cases of Wilson disease and pantothenate kinase-associated neurodegeneration. With the notable exception of SCA3, none of these disorders have prevalence rates similar to synuclein disorders. Moreover, non-synuclein conditions are not typically preceded by RBD, but instead, develop RBD coincidentally or following other neurologic deficits (15; 26; 34; 88; 113; 17; 157; 66; 119).

State boundary dysfunction. REM sleep behavior disorder and narcolepsy are both due to dysfunction in state boundary control, meaning the brain fails to separate features of REM sleep and wakefulness. In narcolepsy, a persistence of REM sleep atonia into wakefulness manifests as sleep paralysis and cataplexy. In RBD, wakeful muscle tone intrudes on REM sleep and dream enactment behavior emerges. Thus, it is not surprising that approximately 50% of patients with narcolepsy also have RBD symptoms (30). This association is strongest among narcolepsy patients with cataplexy, otherwise known as narcolepsy type I (29; 110).

The mechanism of RBD in narcolepsy is likely different from other forms of RBD and related to the failure of orexin to stabilize REM sleep. RBD in patients with narcolepsy demonstrates unique features compared to synuclein etiologies. In particular, dream enactment tends to present earlier, be composed of more simple movements, and is less violent. Further, in addition to REM sleep without atonia RBD patients with narcolepsy have frequent shifts between REM and NREM sleep consistent sleep state boundary dysfunction (29). The risk of future neurodegenerative disease in narcolepsy patients with RBD is not well understood, but likely less than those with iRBD, as phosphorylated alpha-synuclein has not been reported in skin biopsies of narcoleptic patients compared with iRBD (04).

Medication-associated RBD. Psychoactive medications, in particular antidepressants, have long been noted to acutely precipitate or exacerbate dream enactment behavior. Implicated medication classes include tricyclic and tetracyclic antidepressants, monoamine oxidase (MAO) inhibitors, selective-serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and an acetylcholinesterase inhibitor (63; 75; 49). In fact, the induction of RBD-like behavior by phenelzine (an MAO inhibitor) and clomipramine (a tricyclic antidepressant) was repeatedly described in the two decades preceding the seminal 1986 RBD publication (01; 13; 12; 141; 63). Despite the initial reports involving tricyclic antidepressants, given their ubiquity in current clinical practice, selective-serotonin reuptake inhibitors are most commonly implicated in medication-associated RBD. On PSG, drug-induced RBD has more REM sleep-related motor activity in the lower extremities than nondrug-induced RBD (101).

Medication-induced RBD may, in fact, be the most prevalent form of RBD, especially among the young (155; 75). Approximately 10% of depressed patients have an increase in REM sleep motor tone after treatment with sertraline compared to 3% of patients at baseline prior to treatment (167).

Evidence suggests that antidepressants do not represent a de novo induction of RBD, as these patients would have otherwise developed RBD, and ultimately a parkinsonian syndrome later. One study demonstrated that patients with antidepressant-associated RBD have other prodromal markers of alpha-synuclein neurodegeneration, such as hyposmia, constipation, as well as visual and subtle motor impairments (128). In another study, patients with medication-associated RBD had reduced striatal dopamine dysfunction as measured by (18)F-DOPA PET imaging (163). These findings imply that antidepressants are not causing RBD in isolation but instead are unmasking individuals at risk of a neurodegenerative syndrome.

Lesional RBD. Occasionally lesions affecting the pons, medulla, or limbic system, such as malignancies, aneurysms, or white matter disease, will cause RBD, and these cases do not appear to progress to neurodegeneration (103). The first series of patients with RBD investigated with MRI demonstrated dorsal pontomesencephalic area infarctions in 3 of 6 patients (28). Subsequently, reports have emerged of dream enactment behavior following a focal CNS insult from various vascular, demyelinating, neoplastic, and traumatic etiologies (153; 66; 103). Cranial imaging has typically demonstrated pontine tegmentum pathology, although limbic lesions have also been reported. These lesional studies expand nicely on Jouvet’s 1965 feline studies that induced dream enactment after pontine lesions near the locus coeruleus (74).

Inflammatory RBD. RBD can be mediated by inflammatory processes, which implies that immunomodulating therapies may be a plausible therapeutic option. Patients with antibodies against a cell adhesion molecule (IgLON5) commonly have RBD (and RSWA along with severely disturbed sleep architecture and central sleep apnea) that may partially respond to immunosuppression, although most patients relentlessly progress and expire despite immunotherapy. Postmortem examinations reveal hyperphosphorylated tau in the brainstem, suggesting an overlap between autoimmunity and neurodegeneration in these patients (135). Additionally, two cases of RBD, occurring in the setting of paraneoplastic cerebellar degeneration, were responsive to intravenous immunoglobulin (159). Antibodies to leucine rich glioma inactivated-1(LGi1), Ma-2, and dipeptidyl-peptidase-like protein 6 (DPPX) have also been reported to be associated with the development of RBD.

Isolated RBD. Previously, the chronic form of RBD was felt to be idiopathic in the majority of cases. However, the recognition of numerous associated etiologies (neurodegenerative, toxic, lesional) underlying RBD cases have questioned that assumption (66). Further, as noted above, at least the majority of surviving patients with RBD will progress to a parkinsonian or other neurodegenerative condition, leading some to argue that idiopathic RBD does not exist and the term isolated has been recommended to replace idiopathic (66; 60).

Similar to Parkinson disease, RBD is associated with various environmental exposures and behavioral risk factors. In particular, patients with RBD are more likely to smoke, have a history of traumatic brain injury, have fewer years of education, have worked as farmers, and have been exposed to pesticides (131). Heavy alcohol use has also been associated with increased risk of RBD (89).

Epidemiology

	• RBD occurs in 1% to 2% of the general population, with increasing prevalence with advancing age.
	• Although early studies of RBD were predominantly male, more recent studies report equal prevalence in males and females, with males having more violent dream enactment behaviors, leading to a higher proportion of males seeking medical attention for their dream enactment behaviors.

Previous reports of RBD prevalence vary depending on whether a measurement of REM sleep EMG tone by polysomnography was included in the diagnosis. Surveys have revealed that some dream enactment behavior by clinical history alone is nearly universal. In a study of 1140 college-aged students, 98% acknowledged a history of at least one dream enactment behavior symptom (112). Complex dream enactment behavior in the setting of anxious dreams is particularly common in recently postpartum women (111). The first PSG population-based study in RBD found that 1.06% of individuals met PSG criteria for RBD. Importantly, this study showed an equal gender prevalence compared with previous studies that were predominantly male. This is clinically relevant as this suggests that RBD is likely equally common in women, but women are less recognized as they don’t have violent dream enactment behaviors, although they are at equal risk of future neurodegenerative disease. This suggests that great efforts should be made to identify women with RBD in hopes of implementation or study of neuroprotective medications (56).

RBD is more common among the elderly and patients with comorbid neurodegenerative disorders. A general elderly population study utilizing PSG identified RBD in 2% and REM sleep without atonia in the absence of the RBD clinical syndrome in 5% (77). Among Parkinson disease patients, approximately one-third to one-half have RBD (121; 123). The frequency of RBD is even higher among other alpha-synuclein pathologies, with 50% to 80% in dementia with Lewy bodies and 80% to 95% in multiple system atrophy (116).

Among younger adults (younger than 40 years old), RBD is more likely due to antidepressant medications or narcolepsy (15; 87). Fifty percent of patients with narcolepsy have abnormally high REM sleep motor activity (30). Among patients with young onset Parkinson disease, RBD is uncommon (90).

Although RBD is common, with 35 million expected patients worldwide, it is challenging to diagnose, and the vast majority of cases go unrecognized (02). Not unexpectedly, RBD is more commonly diagnosed among patients with other sleep complaints. In a study of 703 patients arriving at a sleep disorders center, 34 (5%) were eventually diagnosed with RBD (47). Importantly, of these 34 RBD patients, only six were referred to the sleep disorder center for suspected RBD; the rest were discovered only after a comprehensive sleep history was taken and polysomnogram performed.

Prevention

	• Currently, no treatments exist to prevent the development of RBD, and there are currently no therapies available to prevent the phenoconversion from isolated RBD to a clinically defined neurodegenerative disease.
	• Growing evidence suggests vigorous aerobic exercise slows the progression of Parkinson disease motor symptoms and may be a reasonable recommendation to delay the phenoconversion of isolated RBD as long as it is safe to do so from a cardiopulmonary standpoint, although this requires further study.

At this time, there are no interventions to prevent the development of RBD associated with neurodegeneration. Further, once RBD has developed, it is uncertain what measures may be taken to prevent or delay the onset of a neurodegenerative disorder. However, RBD is currently used as a biophysiological marker to identify patients at high risk of alpha-synuclein disease, and, hopefully in the future, will help identify neuroprotective therapies that impede parkinsonian disorders. A consortium of multinational sleep investigators, the International Rapid Eye Movement Sleep Behavior Disorder Study Group (IRBDSG), assembles annually in order to promote the development of collaborative clinical trials (145).

Growing evidence suggests that increased levels of exercise in early and mid-life decreases the risk of Parkinson disease and Alzheimer disease. Further, moderate to high intensity aerobic exercise slows the progression of Parkinson disease. Altogether, this suggests that exercise could be a potential therapeutic option to slow RBD progression, although this has not been formally studied (95).

A single proof of concept randomized control trial study evaluating selegiline as a neuroprotective agent in 30 patients with isolated RBD failed to show any difference in rate of phenoconversion between the control and selegiline arms (07). However, there were differences in DAT uptake in the caudate nucleus, but not the putamen between treatment arms at follow-up, suggesting a possibly protective effect and more importantly highlighting the need for biomarker derived measures of disease progression rather than clinical syndrome.

Another intriguing compound, already in use among RBD patients, is melatonin. This agent in high doses (6 to 15 mg) at bedtime abates dream enactment behavior (see Management section). Melatonin has been demonstrated to have antioxidant properties and to protect mitochondrial function, suggesting potential as a neuroprotective agent. However, no large studies of patients with RBD taking melatonin have shown a lower risk of phenoconversion associated with melatonin use (149). Obviously, prospective randomized controlled trials are needed prior to concluding that any agent may prevent or slow the onset of neurodegeneration.

Avoiding antidepressant medications when clinically appropriate and taking measures to reduce risk of stroke can prevent toxic and lesional RBD, respectively. Given the increased risk of RBD in heavy drinkers, decreasing alcohol intake may reduce risk of RBD.

Differential diagnosis

Confusing conditions

The most common disorders that need to be distinguished from RBD include the NREM parasomnias: confusional arousals, sleepwalking, and night terrors. Because of the disproportionate amount of REM sleep at the end of the sleep period, RBD episodes typically occur during the second half of the night in contrast to NREM parasomnias that more often occur in the first half of the night. Patients with RBD are more likely to act out and report dream mentation when awakened from an episode. Dream mentation is more aggressive in RBD, and violent punching and kicking are common. When sleepwalking does result in sleep related injury it is usually sustained during a sudden rush to escape the bedroom, often into or through a window (158).

Behaviors that may mimic RBD can occur during the REM sleep fragmentation associated with obstructive sleep apnea or sleep-related gastroesophageal reflux (15; 66). Further, patients with severe periodic limb movement sleep disorder may also report unpleasant dreams and simulate RBD-like behavior, requiring video polysomnography to distinguish between the two disorders (52).

Less likely etiologies include sleep-related dissociative disorder or nocturnal epilepsy. The behavior in sleep-related dissociative disorder is often prolonged, and polysomnography demonstrates wakefulness throughout the episode. Nocturnal epilepsy is characterized by stereotyped, recurrent, abnormal behaviors, and the EEG may demonstrate epileptic activity (64).

Parasomnia overlap disorder, a combination of both an NREM parasomnia and RBD, is frequently noted and should be considered as well (140). In a series, approximately 21% of all RBD cases and 28% of all sleepwalking/sleep terror cases were later determined to have parasomnia overlap disorder (140). In another report of 93 patients with RBD, 10 patients also had a history of sleepwalking or nocturnal wandering behavior (115).

Trauma associated sleep disorder (TSD) represents an overlap between REM sleep behavior disorder and posttraumatic stress disorder, sharing features with each but has been proposed as a separate entity. Patients with trauma associated sleep disorder have loss of normal skeletal muscle paralysis similar to RBD patients; however, unlike patients with RBD, patients with trauma associated sleep disorder have a history of trauma preceding the development dream enactment behaviors, and dream content typically mirrors that of the individual’s traumatic experience (37).

Diagnostic workup

	• Collateral history from a bedpartner, if available, is invaluable when evaluating a patient with dream enactment behavior.
	• Screening tools focused around the question, “Have you ever been told that you act out your dreams at night?” are highly sensitive and specific for a diagnosis of RBD in the general population.
	• Video polysomnography demonstrating RSWA with or without recorded behaviors is required for a definite diagnosis of RBD and exclusion of mimickers such as obstructive sleep apnea.
	• RBD diagnosed based on a history of dream enactment behaviors without PSG or without demonstration of RSWA on PSG is considered “probable RBD.”
	• Ancillary studies including neuroimaging, nuclear medicine scans, and EEG are not warranted in the workup of RBD unless history and examination are suggestive of parkinsonism, cognitive impairment, or other focal neurologic signs.

Diagnosing RBD requires a thorough clinical evaluation, with a detailed review of the sleep-wake complaints followed by a neuropsychiatric history and examination. A report from a bed partner is particularly helpful as many patients are unable to properly recall the sleep-related events by the time they are discussed with a clinician.

Brief dream enactment behavior occurring in the latter half of the sleep period followed by alertness and orientation on awakening are features that help to distinguish RBD from other parasomnias. This presentation contrasts with sleepwalking in which there is often a lifelong history of prolonged, complex, nonviolent activities, typically emanating from the first half of the sleep period (02).

It is also useful to inquire about ancillary alpha-synuclein symptoms, such as difficulty with smell and bowel motility. When chronic unexplained hyposmia and constipation coexist with RBD, they are highly suggestive of an impending synuclein disorder.

Among patients with Parkinson disease, falling out of bed during sleep is highly suggestive of RBD and a risk factor for sleep-related injury (162).

Diagnostic tools. Screening surveys are available to help identify RBD among certain patient populations. The RBD Questionnaire-Hong Kong (RBDQ-HK) is a validated 13-item measure with scores ranging from 0-100. A higher score indicates greater severity of parasomnia symptoms (85). With a threshold score of 18, the RBDQ-HK has a positive predictive value of 86% and a negative predictive value of 83% (85). The REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) is a 10-item screen, and when administered in combination with a sleep history, a score greater than 4 has a sensitivity of 90% and a specificity of 87% (151). However, it should be pointed out that the RBDSQ performs much better when screening for RBD in the general population when compared with specific patient populations such as Parkinson disease (86).

Intriguingly, two separate groups of investigators have demonstrated an ability to detect RBD with only one question. The Mayo Sleep Questionnaire (MSQ) is a comprehensive sleep health survey, filled out by bed partners, that includes the following question: “Have you ever seen the patient appear to ‘act out his/her dreams’ while sleeping? (punched or flailed arms in the air, shouted or screamed)” (16). A separate group asked a separate question, the RBD Single-Question Screen (RBD1Q): “Have you ever been told, or suspected yourself, that you seem to ‘act out your dreams’ while asleep (for example, punching, flailing your arms in the air, making running movements, etc.)?” (126). The original studies demonstrated high diagnostic sensitivities (MSQ=100%, RBD1Q=94%) and specificities (MSQ=95%, RBD1Q=87%) for these questionnaires. However, both the RBD1Q and the RBD question in the MSQ were noted to have significantly lower specificities when compared to polysomnography (PSG) (MSQ=64%, RBD1Q=68%) (18). Conversely, it has been noted that PSG is not a faultless investigation as it can miss up to 20% of RBD cases (106). Thus, a high number of false negative RBD cases on PSG could explain the seemingly low specificity of the helpful, simple, clinical tools (124).

Visual actigraphy analysis has been shown to accurately diagnose RBD in patients with PSG-proven RBD, especially in combination with clinical history consistent with dream enactment behaviors, providing a potential low-cost alternative for RBD diagnosis when compared with PSG (150). However, further validation of this method is needed.

Polysomnography (PSG). According to current diagnostic criteria, PSG is necessary for definitive diagnosis (69; 02) and is helpful for ruling out other conditions (66). Even when abnormal behavior does not occur during a single night study, RSWA is often present, which in combination with clinical history of dream enactment behavior, can establish a diagnosis (168). Surface EMG of the submentalis, flexor digitorum superficialis, and anterior tibialis muscles are the most commonly analyzed muscles for RSWA. Submentalis and flexor digitorum superficialis are the most sensitive and specific muscles for identification of RBD, and submentalis RSWA appears to be highly specific for underlying synucleinopathy neurodegeneration, even in the absence of clinical dream enactment (48; 97; 102).

By American Academy of Sleep Medicine criteria, a 30-second PSG epoch is scored as RSWA when there is either a sustained elevation of EMG activity (greater than 50% of the 30-second epoch duration compared to minimal amplitude in NREM sleep) or excessive bursts of transient muscle activity (at least half of all 3-second mini epochs on a 30-second page).

RSWA is further quantified by the REM sleep atonia index (RAI) ranging from 0.0 to 1.0 (1.0 completely normal atonia). The RAI demonstrates night to night consistency with minimal variability (19). Defining what quantifies as excessive REM sleep motor activity is challenging, as some degree of REM sleep muscle tone is normal. In order to objectively quantify excessive motor activity, computer-assisted scoring methods have been developed, and an abnormal REM sleep atonia index is often defined as (< 0.88) (43; 49; 99; 46).

Often, early in the course of disease, patients with intermittent REM sleep-related motor behaviors consistent with dream enactment do not have enough RSWA to meet RBD criteria. In two years, however, follow-up PSG testing demonstrates that 69% of patients with these REM sleep behavioral events will convert to RBD (107).

Careful review of the PSG video can discern RBD from other motor parasomnias, and RBD is discernible from other parasomnias as the motor activity is more typically repetitive and pseudohallucinatory, frequently with hand babbling (limb wrist, flexed fingers-like a baby). This subtle dream enactment often involves only the upper extremities and, thus, EMG monitoring of forearm musculature should be included (66). Other REM sleep phenomena are often present, including snoring, and in males, penile tumescence.

REM sleep behavior disorder (polysomnogram)

Note phasic EMG activity of submental and extremity muscles indicating loss of expected REM-related muscle atonia. (Contributed by Dr. Mark Mahowald.)

PSG is also helpful in ruling out conditions such as sleep-disordered breathing, periodic limb movement disorder, and nocturnal epilepsy as a cause of the nocturnal behaviors. The sleep fragmentation of obstructive sleep apnea during REM sleep can lead to dream enactment behavior but resolves with treatment. Periodic limb movement disorder, primarily a NREM sleep phenomena, can be confused with RBD by history, but is easily discernible on polysomnography. Nocturnal epilepsy should be suspected, and a 32-lead EEG montage added, especially if there is a history of stereotyped, abnormal, and repetitive behaviors (64).

Other clinical investigations. Additional testing such as neuroimaging, EEG, and neuropsychological batteries are warranted only if there is further evidence suggesting a neuropsychiatric disorder or focal neurologic deficits on examination. The practical clinical utility of tests that identify CNS dopamine dysfunction, such as a DaTSCAN, or other markers of synuclein pathology, such as MIBG cardiac scintography, FDG-PET scan, or regional cerebral blood flow has yet to be determined clinically, although they are active areas of investigation in research (59).

Management

	• Initial management of all patients with RBD involves ensuring a safe sleeping environment and removing objects that could lead to injury if hit or utilized during an RBD episode to reduce risk of injury.
	• Clonazepam (0.5 to 1.0 mg) and melatonin (6 to 15 mg) at bedtime are considered first-line options for pharmacologic management in RBD and are thought to be equally effective with melatonin having fewer side effects.
	• Acetylcholinesterase inhibitors, dopamine agonists, sodium oxybate, and a bed alarm may be efficacious in certain subpopulations of RBD patients.
	• Despite multiple medication trials, it is common for patients to have some amount of residual dream enactment behaviors.
	• Disclosing the risk of phenoconversion to patients diagnosed with isolated RBD is generally recommended; however, individual patient factors such as medication induced RBD versus the presence of mild bradykinesia or cognitive impairment should be taken into account when discussing this risk with each patient.

Management should initially focus on patient and bed partner safety, by modifying the sleeping environment. Subsequently, the clinician should eliminate aggravating agents, as well as identify and treat comorbid sleep disorders. Unfortunately, frequency of dream enactment behaviors is not predictive of injury, so bedroom safety must be addressed with all patients with RBD at a minimum (100). Most cases of toxic RBD are self-limited following discontinuation of offending medication, and dream enactment behavior typically resolves if underlying obstructive sleep apnea is treated. When violent nocturnal behaviors persist despite these interventions or in situations with a high probability of injury, pharmacotherapy is appropriate. However, there is an absence of large randomized controlled trials, and systematic reviews as well as professional societies have found insufficient evidence at present to make definitive conclusions regarding RBD therapy, although small randomized, placebo-controlled studies of clonazepam and melatonin have failed to show significant improvement in RBD symptoms with clonazepam or melatonin compared to placebo; however, it is possible that in the case of melatonin that patients were simply insufficiently dosed (146; 134; 76; 147). Instead, a consensus has arisen based on original reports, case series, and small clinical trials. Ultimately, clonazepam and melatonin, the mainstays of treatment for RBD, reduce the frequency and severity of dream enactment behaviors as well as injury potential, but complete elimination of dream enactment behaviors is rare.

Clonazepam. Clonazepam has been the most widely prescribed agent for RBD, and approximately 90% of patients initially respond well to low doses (0.5 to 1.0 mg) (115; 144). Clonazepam decreases the risk for dream enactment injury when administered at bedtime (42). The agent also appears to be effective in cases of Parkinson disease and narcolepsy (144; 142).

Clonazepam’s therapeutic mechanism in RBD is not fully understood, although it is thought that clonazepam may decrease the frequency of unpleasant nightmares, thus, decreasing dream enactment behaviors. In general, it is thought that clonazepam does not impact REM sleep without atonia, but some studies have suggested it may have an impact (84; 21). Long-term studies of clonazepam range from sustained benefit without dose escalation to others with a high incidence of dose escalation and treatment failure (142; 144; 55; 03; 66). In a series, 58% of patients on clonazepam reported clinically significant adverse effects, with 50% either stopping the agent or reducing the dose (03). Further, a prospective study of clonazepam in treatment-naive patients did not demonstrate an improvement in symptoms (44). Also, clonazepam is particularly problematic in the setting of advanced neurodegenerative disease where it’s prolonged duration of action may result in morning sedation as well as cognitive and gait impairment (66). A double-blind placebo-controlled trial of 0.5 mg of clonazepam in Parkinson disease patients with probable RBD found no difference between clonazepam and placebo-treated patients (147).

Melatonin. Several studies have suggested that melatonin may be an effective and safe first-line treatment for RBD. Melatonin is an endogenous hormone normally secreted by the pineal gland in response to evening darkness and helps entrain circadian rhythms. Exogenous immediate-release melatonin in high doses at bedtime (6 to 15 mg) augments REM sleep atonia and improves RBD symptoms (66). Although the exact mechanism of melatonin in RBD is unknown, it may be realigning the circadian rhythmicity of REM sleep. One interesting study demonstrated that patients with untreated RBD lose circadian-dependent features of REM sleep and often have a phase delayed circadian rhythm (08), whereas another study reported smaller pineal gland volume in Alzheimer disease patients with probable RBD who did not meet criteria for dementia with Lewy bodies (117).

Investigators have reported that melatonin is effective either in combination with clonazepam or as sole therapy (152; 81). Importantly, a direct comparison study noted that melatonin was equal to clonazepam in treatment efficacy and superior in side effect profile. Patients on melatonin reported fewer adverse effects, in particular falls and injuries, compared to clonazepam (96). In the setting of Parkinson disease, melatonin is a particularly intriguing option as it is only mildly sedating. A meta-analysis concluded that melatonin was efficacious in RBD among patients with neurodegeneration (169). On the other hand, two placebo-controlled trials of 2 mg, 4 mg, and 6 mg of prolonged release melatonin found no significant improvement in RBD symptoms in patients with either iRBD or Parkinson disease-RBD (76; 54). The reason prolonged-release melatonin has been less effective for RBD symptoms than immediate-release melatonin is unclear. It is likely that trial design has a strong influence (prolonged-release melatonin has been studied in double-blind placebo-controlled studies whereas immediate-release melatonin has been reported in observational or open-label studies, which are prone to bias), but it is also possible that doses trialed for prolonged-release melatonin have been insufficient as the median effective dose for melatonin has been reported to be 6 mg, which is the maximum dose studied for prolonged-release melatonin. Future controlled dose-finding trials comparing immediate- and prolonged-release melatonin are needed to answer this important question.

Melatonin suppresses both phasic and tonic REM sleep motor activity, and its effect persists for weeks after the agent is discontinued (15; 81). Also, ramelteon, a melatonin agonist, was reported to effectively treat RBD in two cases, but was ineffective in reducing objective dream enactment behaviors or altering RSWA in a small open-label clinical trial (114; 36).

Rivastigmine. Cholinergic agents may be useful in RBD among patients who have failed conventional therapy. Two placebo-controlled crossover trials noted that the cholinesterase inhibitor rivastigmine reduced the number of dream enactment behavior episodes among patients who already had mild cognitive impairment, thus an indication for rivastigmine (33; 20).

Pramipexole. Pramipexole may be effective in mild cases of RBD, in particular, those associated with frequent periodic limb movements. One investigation noted that compared to clonazepam-responsive patients, pramipexole-responsive patients had more mild disease at baseline as measured by REM sleep atonia (138). Similar to treating obstructive sleep apnea in RBD, pramipexole may decrease nocturnal behaviors by reversing a sleep fragmenting condition, periodic limb movements. Another pramipexole study in patients with RBD reported a decrease in distressing nocturnal behaviors along with a decrease in periodic limb movements, but no effect on REM sleep atonia (137). Alternatively, it may be that only RBD patients with abnormal dopamine uptake on DATSCAN may find RBD treatment response with dopamine agonists such as pramipexole, although this requires further study.

Other therapies. Other agents with some reported success include prazosin, imipramine, carbamazepine, rotigotine, levodopa, donepezil, sodium oxybate, triazolam, zopiclone, quetiapine, clozapine, and cannabidiol (23; 66). However, the data supporting efficacy of these agents are weak.

Surgical treatments for Parkinson disease including deep brain stimulation do not appear to strikingly improve RBD. There is often an improvement in subjective sleep quality and sleep architecture on polysomnography; however, there has been no noted improvement in dream enactment behavior, and in some cases, it can actually worsen (27; 78). These findings are not unexpected as the target of deep brain stimulation, the subthalamic nucleus, does not have a known effect on REM sleep.

Interestingly, RBD symptoms tend to decrease with progression of the underlying neurodegenerative condition, whereas RSWA increases, and RBD patients with a diagnosed neurodegenerative disease are less likely to be injured by their dream enactment behaviors than those with iRBD (99; 45; 166). Although the mechanism of this moderation of dream enactment behavior is uncertain, it may be due to diffuse impairment of motor circuits with advanced disease, leading to the replacement of strong phasic bursts of RSWA seen in iRBD with low amplitude continuous tonic muscle activity that is more characteristically seen in RBD patients with comorbid neurodegenerative disease (98; 45).

Refractory RBD and bed alarm therapy. Medication refractory RBD is a daunting and potentially life-threatening condition with limited management options. Exiting the bed while acting out a dream is a particularly high-risk behavior and may result in severe traumatic injury (143). Intriguingly, the low arousal threshold and rapid transition to alert wakefulness from REM sleep offers a therapeutic window to halt behavior prior to sleep-related injury (73). Despite apparent unconsciousness during REM sleep, the brain is readily responsive to complex auditory sound processing (73; 10). This contrasts with the high arousal threshold of NREM sleep often demonstrated by the inability to redirect or wake up sleepwalkers (a NREM parasomnia) (120). Further, other REM pathologies, such as nightmare disorder, can be treated with verbal redirection (64).

A study of patients with medication refractory RBD and sleep-related injury demonstrated the utility of a customized bed alarm that delivered a calming message at the onset of dream enactment behavior (65). Ideal voices, typically those of family members, were identified and commands to halt dream enactment behavior were then recorded (eg, “Dave, you are having a dream, lay back down”). Subsequently, when the patient arose during sleep, the voice emanated from a bedside speaker on a repeating loop until the patient returned to lying down on the pressure pad.

In conclusion, there is a clinical consensus that clonazepam and melatonin are reasonable first-line therapies; however, more methodologically rigorous studies are needed to convincingly prove efficacy. Importantly, agencies that regulate drug approval do not recognize clonazepam, or any other agent, so its use is off-label. The American Academy of Sleep Medicine has assembled a task force to review and provide management recommendations for RBD. The task force is expecting to publish their findings in 2021.

Patient counseling. The diagnosis of isolated RBD provides an ethical dilemma for many clinicians in terms of who to inform of the neurodegenerative risk associated with RBD. Although circumstances surrounding each individual patient should be taken into account when deciding to disclose the risk for future neurodegenerative disease, general consensus is to inform patients of this risk; however, the degree of granularity in which this risk is discussed is variable (154). In particular, if patients develop RBD after age 60, are not taking antidepressants, and already have nonmotor features of synucleinopathy, they should certainly be informed of the risk of neurodegenerative disease and referred to a center specializing in RBD. For individuals diagnosed with RBD at a young age (ie, less than 50 years of age), are associated with antidepressant medications, and have the presence of structural lesions or autoimmunity, the risk of neurodegeneration is less clear, and clinicians should use their own judgement whether to inform patients of neurodegenerative risk, although it would be reasonable to observe these patients closely for evolving signs of neurodegeneration (05).

References

01: Akindele MO, Evins JI, Oswald I. Mono-amine oxidase inhibitors, sleep and mood. Electroencephalogr Clin Neurophysiol 1970;29(1):47-56. PMID 4194050
02: American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual. (AASM ICSD-3). 3rd edition. Westchester, IL: American Academy of Sleep Medicine, 2014.
03: Anderson KN, Shneerson JM. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 2009;5(3):235-9. PMID 19960644
04: Antelmi E, Pizza F, Donadio V, et al. Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients. Ann Clin Transl Neurol 2019;6(9):1872-6. PMID 31386270
05: Arnaldi D, Antelmi E, St Louis EK, Postuma RB, Arnulf I. Idiopathic REM sleep behavior disorder and neurodegenerative risk: To tell or not to tell to the patient? How to minimize the risk? Sleep Med Rev 2017;36:82-95. PMID 28082168
06: Arnaldi D, Chincarini A, Hu MT, et al. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain 2021a;144(1):278-87. PMID 33348363
07: Arnaldi D, Famà F, Girtler, et al. Rapid eye movement sleep behavior disorder: A proof-of-concept neuroprotection study for prodromal synucleinopathies. Eur J Neurol 2021b;28(4):1210-7. PMID 33275819
08: Arnaldi D, Latimier A, Leu-Semenescu S, Vidailhet M, Arnulf I. Loss of REM sleep features across nighttime in REM sleep behavior disorder. Sleep Med 2016;17:134-7. PMID 26847988
09: Arnulf I, Neutel D, Herlin B, et al. Sleepiness in idiopathic REM sleep behavior disorder and Parkinson disease. Sleep 2015;38(10):1529-35. PMID 26847988
10: Atienza M, Cantero JL. Complex sound processing during human REM sleep by recovering information from long-term memory as revealed by the mismatch negativity (MMN). Brain Res 2001;901(1-2):151-60. PMID 11368962
11: Barone DA, Ebben MR, Samie A, Mortara D, Krieger AC. Autonomic dysfunction in isolated rapid eye movement sleep without atonia. Clin Neurophysiol 2015;126(4):731-5. PMID 25193749
12: Bental E, Lavie P, Sharf B. Severe hypermotility during sleep in treatment of cataplexy with clomipramine. Isr J Med Sci 1979;15(7):607-9. PMID 478825
13: Besset A. Effect of antidepressants on human sleep. Adv Biosci 1978;21:141-8. PMID 755712
14: Blumberg MS, Plumeau AM. A new view of "dream enactment" in REM sleep behavior disorder. Sleep Med Rev 2016;30:34-42. PMID 26802823
15: Boeve BF. REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 2010;1184:15-54. PMID 20146689
16: Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community based sample. J Clin Sleep Med 2013a;9(5):475-80. PMID 23674939
17: Boeve BF, Silber MH, Ferman TJ, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without coexisting neurologic disorder. Sleep Med 2013b;14(8):754-62. PMID 25068842
18: Bolitho SJ, Naismith SL, Terpening Z, et al. Investigating rapid eye movement sleep without atonia in Parkinson’s disease using the rapid eye movement sleep behavior disorder screening questionnaire. Mov Disord 2014;29(6):736-42. PMID 24619826
19: Bolitho SJ, Naismith SL, Terpening Z, et al. Investigating the night-to-night variability of REM without atonia in Parkinson’s disease. Sleep Med 2015;16(1):190-3. PMID 25488601
20: Brunetti V, Losurdo A, Testani E, et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. Curr Alzheimer Res 2014;11(3):267-73. PMID 24597506
21: Byun JI, Shin YY, Seong YA, et al. Comparative efficacy of prolonged-release melatonin versus clonazepam for isolated rapid eye movement sleep behavior disorder. Sleep Breath 2022. [Epub ahead of print] PMID 35141811
22: Carli G, Caminiti SP, Galbiati A, et al. In-vivo signatures of neurodegeneration in isolated rapid eye movement sleep behaviour disorder. Eur J Neurol 2020;27(7):1285-95. PMID 32170820
23: Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviors associated with rapid eye movement sleep behavior disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther 2014;39(5):564-6. PMID 24845114
24: Chahine LM, Xie SX, Simuni T, et al. Longitudinal changes in cognition in early Parkinson’s disease patients with REM sleep behavior disorder. Parkinsonism Relat Disord 2016;27:102-6. PMID 27010070
25: Chen TZ, Xu GJ, Zhou GA, Wang JR, Chan P, Du YF. Postural sway in idiopathic rapid eye movement sleep behavior disorder: A potential marker of prodromal Parkinson’s disease. Brain Res 2014;1559:26-32. PMID 24602694
26: Chokroverty S, Bhat S, Rosen D, Farheen A. REM behavior disorder in myotonic dystrophy type 2. Neurology 2012;78(24):2004. PMID 22689737
27: Cicolin A, Lopiano L, Zibetti M, et al. Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Sleep Med 2004;5(2):207-10. PMID 15033145
28: Culebras A, Moore JT. Magnetic resonance findings in REM sleep behavior disorder. Neurology 1989;39(11):1519-23. PMID 2812333
29: Dauvilliers Y, Jennum P, Plazzi G. REM sleep behavior disorder and REM sleep without atonia in narcolepsy. Sleep Med 2013a;14(8):775-81. PMID 23219054
30: Dauvilliers Y, Rompre S, Gagnon JF, Vendette M, Petit D, Montplaisir J. REM sleep characteristics in narcolepsy and REM sleep behavior disorder. Sleep 2007;30(7):844-9. PMID 17682654
31: De Marzi R, Seppi K, Hogl B, et al. Loss of dorsolateral nigral hyperintensity on 3.0 Tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 2016;79(6):1026-30. PMID 27016314
32: De Pablo-Fernández E, Lees AJ, Holton JL, Warner TT. Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol 2019;76(4):470-9. PMID 30640364
33: Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord 2012;27(4):559-61. PMID 22290743
34: Ebben MR, Shahbazi M, Lange DJ, Krieger AC. REM behavior disorder associated with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13(5):473-4. PMID 22670878
35: Ehrminger M, Latimier A, Pyatigorskaya N, et al. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain 2016;139(Pt 4):1180-8. PMID 26920675
36: Esaki Y, Kitajima T, Koike S, et al. An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder. J Clin Sleep Med 2016;12(5):689-93. PMID 26857053
37: Feemster JC, Smith KL, McCarter SJ, et al. Trauma-associated sleep disorder: a posttraumatic stress/REM sleep behavior disorder mash-up? J Clin Sleep Med 2019;15(2):345-9. PMID 30736880
38: Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 2015;72(8):863-73. PMID 26076039
39: Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. Brain 2019;142(7):2051-67. PMID 31111143
40: Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain 2017;140(7):1959-76. PMID 28549077
41: Ferini-Strambi L, Oertel W, Dauvilliers Y, et al. Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study. J Neurol 2014;261(6):1112-8. PMID 24687894
42: Fernandez-Arcos, Iranzo A, Serradell M, Gaig C, Santamaria J. The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation: a study in 203 consecutive patients. Sleep 2016;39(1):121-32. PMID 26940460
43: Ferri R, Gagnon JF, Postuma RB, et al. Comparison between and automatic and visual scoring method of the chin muscle tone during rapid eye movement sleep. Sleep Med 2014;15(6):661-5. PMID 24831249
44: Ferri R, Marelli S, Ferini-Strambi L, et al. An observational clinical and video-polysomnographic study of the effects of clonazepam in REM sleep behavior disorder. Sleep Med 2013;14(1):24-9. PMID 23098778
45: Figorilli M, Marques AR, Vidal T, et al. Does REM sleep behavior disorder change in the progression of Parkinson's disease? Sleep Med 2020;68:190-8. PMID 32044557
46: Frandsen R, Nikolic M, Zoetmulder M, Kempfner L, Jennum P. Analysis of automated quantification of motor activity in REM sleep behavior disorder. J Sleep Res 2015;24(5):583-90. PMID 25923472
47: Frauscher B, Gschliesser V, Brandauer E, et al. REM sleep behavior disorder in 703 sleep-disorder patients: the importance of eliciting a comprehensive sleep history. Sleep Med 2010;11(2):167-71. PMID 20022299
48: Frauscher B, Iranzo A, Gaig C, et al. Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep 2012a;35(6):835-47. PMID 22654203
49: Frauscher B, Jennum P, Ju YE, et al. Comorbidity and medication in REM sleep behavior disorder: a multicenter case-control study. Neurology 2014;82(12):1076-9. PMID 24553425
50: Frauscher B, Nomura T, Duerr S, et al. Investigation of autonomic function in idiopathic REM sleep behavior disorder. J Neurol 2012b;259(6):1056-61. PMID 22064976
51: Garcia-Gomar MG, Videnovic A, Singh K, et al. Disruption of brainstem structural connectivity in REM sleep behavior disorder using 7 Tesla magnetic resonance imaging. Mov Disord 2022;37(4):847-53. PMID 34964520
52: Gaig C, Iranzo A, Pujol M, Perez H, Santamaria J. Periodic limb movements during sleep mimicking REM sleep behavior disorder: a new form of periodic limb movement disorder. Sleep 2017;40(3). PMID 28364416
53: Gersel Stokholm M, Iranzo A, Østergaard K, et al. Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. Eur J Neurol 2020;27(4):644-52. PMID 31725927
54: Gilat M, Coeytaux Jackson A, Marshall NS, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: a randomised controlled trial. Mov Disord 2020;35(2):344-9. PMID 31674060
55: Gugger JJ, Wagner ML. Rapid eye movement sleep behavior disorder. Ann Pharmacother 2007;41(11):1833-41. PMID 17925503
56: Haba-Rubio J, Frauscher B, Marques-Vidal P, et al. Prevalence and determinants of REM sleep behavior disorder in the general population. Sleep 2018;41(2):zsx197. PMID 29216391
57: Hackius M, Werth E, Sürücü O, Baumann CR, Imbach LL. Electrophysiological evidence for alternative motor networks in REM sleep behavior disorder. J Neurosci 2016;36(46):11795-11800. PMID 27852786
58: Hall JM, Shine JM, O’Callaghan C, et al. Freezing of gait and its associations in the early and advanced clinical motor stages of Parkinson’s disease: a cross-sectional study. J Parkinsons Dis 2015;5(4):881-91. PMID 26444088
59: Heller J, Brcina N, Dogan I, et al. Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) - a systematic review on potential biomarkers for neurodegeneration. Sleep Med Rev 2017;34:23-33. PMID 27542516
60: Hogl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration - an update. Nat Rev Neurol 2018;14(1):40-55. PMID 29170501
61: Holtbernd F, Gagnon JF, Postuma RB, et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 2014;82(7):620-7. PMID 24453082
62: Honeycutt L, Montplaisir JY, Gagnon JF, et al. Glucocerebrosidase mutations and phenoconversion of REM sleep behavior disorder to parkinsonism and dementia. Parkinsonism Relat Disord 2019;65:230-3. PMID 31076265
63: Hoque R, Chesson AL Jr. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med 2010;6(1):79-83. PMID 20191944
64: Howell MJ. Parasomnias: an updated review. Neurotherapeutics 2012;9(4):752-75. PMID 22965264
65: Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med 2011;7(6):639-44A. PMID 22171203
66: Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol 2015;72(6):707-12. PMID 25867792
67: Hsieh KC, Nguyen D, Siegel JM, Lai YY. New pathways and data on REM sleep behaviour disorder in a rat model. Sleep Med 2013;14(8):719-28. PMID 23058690
68: Hu Y, Yu SY, Zuo LJ, et al. Parkinson disease with REM sleep behavior disorder: features, alpha-synuclein, and inflammation. Neurology 2015;84(9):888-94. PMID 25663225
69: Iber C, Ancoli-Israel S, Chesson A, Quan SF for the American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. Westchester, Illinois: American Academy of Sleep Medicine, 2007.
70: Iranzo A, Fairfoul G, Ayudhaya ACN, et al. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. Lancet Neurol 2021;20(3):203-12. PMID 33609478
71: Iranzo A, Stefani A, Serradell M, et al. Characterization of patients with longstanding idiopathic REM sleep behavior disorder. Neurology 2017;89(3):242-8. PMID 28615430
72: Janzen A, Kogan RV, Meles SK, et al. Rapid eye movement sleep behavior disorder: abnormal cardiac image and progressive abnormal metabolic brain pattern. Mov Disord 2022;37(3):624-9. PMID 34796976
73: Jones BE. Paradoxical sleep and its chemical/structural substrates in the brain. Neuroscience 1991;40(3):637-56. PMID 2062436
74: Jouvet M, Delorme F. Locus coeruleus et sommeil paradoxal. C R Soc Biol 1965;159:895-9.
75: Ju YE, Larson-Prior L, Duntley S. Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants. Sleep Med 2011;12(3):278-83. PMID 21317035
76: Jun JS, Kim R, Byun JI, et al. Prolonged-release melatonin in patients with idiopathic REM sleep behavior disorder. Ann Clin Transl Neurol 2019;6(4):716-22. PMID 31019996
77: Kang SH, Yoon IY, Lee SD, Han JW, Kim TH, Kim KW. REM sleep behavior disorder in the Korean elderly population: prevalence and clinical characteristics. Sleep 2013;36(8):1147-52. PMID 23904674
78: Kim YE, Jeon BS, Paek SH, et al. Rapid eye movement sleep behavior disorder after bilateral subthalamic stimulation in Parkinson’s disease. J Clin Neurosci 2015;22(2):315-9. PMID 25439757
79: Kogan RV, Janzen A, Meles SK, et al. Four-year follow-up of [18 F]fluorodeoxyglucose positron emission tomography-based Parkinson's disease-related pattern expression in 20 patients with isolated rapid eye movement sleep behavior disorder shows prodromal progression. Mov Disord 2021;36(1):230-5. PMID 32909650
80: Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 2013;136(Pt 8):2419-31. PMID 23884810
81: Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res 2010;19(4):591-6. PMID 20561180
82: Leclair-Visonneau L, Clairembault T, Coron E, et al. REM sleep behavior disorder is related to enteric neuropathology in Parkinson disease. Neurology 2017;89(15):1612-8. PMID 28887374
83: Li K, Li SH, Su W, Chen HB. Diagnostic accuracy of REM sleep behavior disorder screening questionnaire: a meta-analysis. Neurol Sci 2017a;38(6):1039-46. PMID 28314940
84: Li SX, Lam SP, Zhang J, et al. A prospective, naturalistic follow-up study of treatment outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep Med 2016;21:114-20. PMID 27448481
85: Li SX, Wing YK, Lam SP, et al. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK). Sleep Med 2010;11(1):43-8. PMID 19945912
86: Li Y, Kang W, Yang Q, et al. Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. Neurology 2017b;88(16):1493-1500. PMID 28330956
87: Lloyd R, Tippmann-Peikert M, Slocumb N, Kotagal S. Characteristics of REM sleep behavior disorder in childhood. J Clin Sleep Med 2012;8(2):127-31. PMID 22505856
88: Lo Coco D, Cupidi C, Mattaliano A, Baiamonte V, Realmuto S, Cannizzaro E. REM sleep behavior disorder in a patient with frontotemporal dementia. Neurol Sci 2012;33(2):371-3. PMID 21751100
89: Ma C, Pavlova M, Li J, et al. Alcohol consumption and probable rapid eye movement sleep behavior disorder. Ann Clin Transl Neurol 2018;5(10):1176-83. PMID 30349852
90: Mahale R, Yadav R, Pal PK. Rapid eye movement sleep behavior disorder in young-and older-onset Parkinson disease: a questionnaire-based study. Sleep Med 2014;15(6):642-6. PMID 24780134
91: Mahlknecht P, Iranzo A, Hogl B, et al. Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 2015;84(7):654-8. PMID 25609758
92: Marchand DG, Montplaisir J, Postuma RB, Rahayel S, Gagnon JF. Detecting the cognitive prodrome of dementia with Lewy bodies: a prospective study of REM sleep behavior disorder. Sleep 2017;40(1). PMID 28364450
93: Mariotti P, Quaranta D, Di Giacopo R, et al. Rapid eye movement sleep behavior disorder: a window on the emotional world of Parkinson disease. Sleep 2015;38(2):287-94. PMID 25325501
94: Mayer G, Bitterlich M, Kuwert T, Ritt P, Stefan H. Ictal SPECT in patients with rapid eye movement sleep behaviour disorder. Brain 2015;138(Pt 5):1263-70. PMID 25732183
95: McCarter SJ, Boeve BF, Graff-Radford NR, Silber MH, St Louis EK. Neuroprotection in idiopathic REM sleep behavior disorder: a role for exercise? Sleep 2019a;42(6):zsz064. PMID 31184756
96: McCarter SJ, Boswell CL, St Louis EK, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med 2013;14(3):237-42. PMID 23352028
97: McCarter SJ, Feemster JC, Tabatabai GM, et al. Submentalis rapid eye movement sleep muscle activity: a potential biomarker for synucleinopathy. Ann Neurol 2019c;86(6):969-74. PMID 31621939
98: McCarter SJ, Sandness DJ, McCarter AR, et al. REM sleep muscle activity in patients with idiopathic REM sleep behavior disorder predicts phenoconversion. Neurology 2019b;93(12):e1171-9. PMID 31420463
99: McCarter SJ, St Louis EK, Boswell CL, et al. Factors associated with injury in REM sleep behavior disorder. Sleep Med 2014a;15(11):1332-8. PMID 25194585
100: McCarter SJ, St Louis EK, Duwell EJ, et al. Diagnostic thresholds for quantitative REM sleep phasic burst duration, phasic and tonic muscle activity, and REM atonia index in REM sleep behavior disorder with and without comorbid obstructive sleep apnea. Sleep 2014b;37(10):1649-62. PMID 25197816
101: McCarter SJ, St Louis EK, Sandness DJ, et al. Antidepressants increase REM sleep muscle tone in patients with and without REM sleep behavior disorder. Sleep 2015a;38(6):907-17. PMID 25325487
102: McCarter SJ, Tabatabai GM, Jong HY, et al. REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. Neurology 2020;94(1):e15-e29. PMID 31831602
103: McCarter SJ, Tippmann-Peikert M, Sandess DJ, et al. Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Med 2015b;16(12):1502-10. PMID 26611948
104: McDade EM, Boot BP, Christianson TJ, et al. Subtle gait changes in patients with REM sleep behavior disorder. Mov Disord 2013;28(13):1847-53. PMID 24130124
105: Miglis MG, Zitser J, Schneider L, et al. Cutaneous α-synuclein is correlated with autonomic impairment in isolated rapid eye movement sleep behavior disorder. Sleep 2021;44(12):zsab172. PMID 34244806
106: Montplaisir J, Gagnon JF, Fantini ML, et al. Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. Mov Disord 2010;25(13):2044-51. PMID 20818653
107: Muntean ML, Trenkwalder C, Walters AS, Mollenhauer B, Sixel-Doring F. REM Sleep behavioral events and dreaming. J Clin Sleep Med 2015;11(5):537-41. PMID 25665694
108: Murray ME, Ferman TJ, Boeve BF, et al. MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology 2013;81(19):1681-9. PMID 24107861
109: Nardone R, Bergmann J, Brigo F, et al. Functional evaluation of central cholinergic circuits in patients with Parkinson's disease and REM sleep behavior disorder: a TMS study. J Neural Transm 2013;120(3):413-22. PMID 22903350
110: Nevsimalova S, Pisko J, Buskova J, et al. Narcolepsy: clinical differences and association with other sleep disorders in different age groups. J Neurol 2013;260(3):767-75. PMID 23070467
111: Nielsen T, Paquette T. Dream-associated behaviors affecting pregnant and postpartum women. Sleep 2007;30(9):1162-9. PMID 17910388
112: Nielsen T, Svob C, Kuiken D. Dream-enacting behaviors in a normal population. Sleep 2009;32(12):1629-36. PMID 20041599
113: Nomura T, Inoue Y, Takigawa H, Nakashima K. Comparison of REM sleep behaviour disorder variables between patients with progressive supranuclear palsy and those with Parkinson's disease. Parkinsonism Relat Disord 2012;18(4):394-6. PMID 22115673
114: Nomura T, Kawase S, Watanabe Y, Nakashima K. Use of ramelteon for the treatment of secondary REM sleep behavior disorder. Intern Med 2013;52(18):2123-6. PMID 24042525
115: Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123(Pt 2):331-9. PMID 10648440
116: Palma JA, Fernandez-Cordon C, Coon EA, et al. Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin Auton Res 2015;25(1):69-75. PMID 25739474
117: Park J, Suh SW, Kim GE, et al. Smaller pineal gland is associated with rapid eye movement sleep behavior disorder in Alzheimer's disease. Alzheimers Res Ther 2020;12(1):157. PMID 33220712
118: Parkinson J. An Essay on the Shaking Palsy. Whittingham and Rowland: London, 1817.
119: Pedroso JL, Braga-Neto P, Escorcio-Bezerra ML, et al. Non-motor and extracerebellar features in spinocerebellar ataxia type 2. Cerebellum 2017;16(1):34-9. PMID 26825292
120: Pilon M, Montplaisir J, Zadra A. Precipitating factors of somnambulism: impact of sleep deprivation and forced arousals. Neurology 2008;70(24):2284-90. PMID 18463368
121: Plomhause L, Dujardin K, Duhamel A, et al. Rapid eye movement sleep behavior disorder in treatment-naïve Parkinson disease patients. Sleep Med 2013;14(10):1035-7. PMID 23890957
122: Pont-Sunyer C, Iranzo A, Gaig C, et al. Sleep disorders in parkinsonism and nonparkinsonism LRRK2 mutation carriers. PLoS ONE 2015;10(7):e0132368. PMID 26177462
123: Poryazova R, Oberholzer M, Baumann CR, Bassetti CL. REM sleep behavior disorder in Parkinson’s disease: a questionnaire-based survery. J Clin Sleep Med 2013;9(1):55-9A. PMID 23319905
124: Postuma RB. Diagnosing REM sleep behavior disorder in Parkinson’s disease-can we avoid the polysomnogram. Mov Disord 2014;29(6):713-4. PMID 24619856
125: Postuma RB, Adler CH, Dugger BN, et al. REM sleep behavior disorder and neuropathology in Parkinson’s disease. Mov Disord 2015c;30(10):1413-7. PMID 26265105
126: Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord 2012b;27(7):913-6. PMID 22729987
127: Postuma RB, Gagnon JF, Bertrand JA, et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015b;84(11):1104-13. PMID 25681454
128: Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Mov Disord 2013a;28(5):597-604. PMID 23554107
129: Postuma RB, Iranzo A, Hogl B, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 2015a;77(5):830-9. PMID 25767079
130: Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019;142(3):744-59. PMID 30789229
131: Postuma RB, Montplaisir JY, Pelletier A, et al. Environmental risk factors for REM sleep behavior disorder: a multicenter case-control study. Neurology 2012a;79(5):428-34. PMID 22744670
132: Postuma RB, Pelletier A, Gagnon JF, Montplaisir J. Evolution of prodromal multiple system atrophy from REM sleep behavior disorder: a descriptive study. J Parkinsons Dis 2022;12(3):983-91. PMID 35094998
133: Rahayel S, Gaubert M, Postuma RB, et al. Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorder. Sleep 2019;42(6). PMID 30854555
134: Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: systematic review and meta-analysis. Parkinsonism Relat Disord 2016;27:25-34. PMID 27010071
135: Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep disordered breathing associated with antibodies to IgLON5: a case series, characterization of the antigen, and post-mortem study. Lancet Neurol 2014;13(6):575-86. PMID 24703753
136: Salsone M, Vescio B, Fratto A, et al. Cardiac sympathetic index indentifies patients with Parkinson’s disease and REM behavior disorder. Parkinsonism Relat Disord 2016;26:62-6. PMID 27013172
137: Sasai T, Inoue Y, Matsuura M. Effectiveness of pramipexole, a dopamine agonist, on rapid eye movement sleep behavior disorder. Tohoku J Exp Med 2012a;226(3):177-81. PMID 22333559
138: Sasai T, Matsuura M, Inoue Y. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 2013a;19(2):153-7. PMID 22989561
139: Sasai-Sakuma T, Nishio Y, Yokoi K, Mori E, Inoue Y. Pareidolias in REM sleep behavior disorder: a possible predictive marker of Lewy body diseases? Sleep 2017;40(2). PMID 28364496
140: Schenck CH, Boyd JL, Mahowald MW. A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM sleep behavior disorder in 33 polysomnographically confirmed cases. Sleep 1997;20(11):972-81. PMID 9456462
141: Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 1986;9(2):293-308. PMID 3505730
142: Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996;46(2):388-93. PMID 8614500
143: Schenck CH, Lee SA, Bornemann MA, Mahowald MW. Potentially lethal behaviors associated with rapid eye movement sleep behavior disorder: review of the literature and forensic implications. J Forensic Sci 2009;54(6):1475-84. PMID 19788703
144: Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep 2002;25(2):120-38. PMID 11902423
145: Schenck CH, Montplaisir JY, Frauscher B, et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 2013;14(8):795-806. PMID 23886593
146: Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26 Suppl 3:S42-80. PMID 22021174
147: Shin C, Park H, Lee WW, Kim HJ, Kim HJ, Jeon B. Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. J Neurol Sci 2019;401:81-6. PMID 31035190
148: Sorensen GL, Mehlsen J, Jennum P. Reduced activity in idiopathic rapid-eye-movement sleep behavior disorder and Parkinson’s disease. Auton Neurosci 2013;179(1-2):138-41. PMID 24021939
149: Srinivasan V, Cardinali DP, Srinivasan US, et al. Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord 2011;4(5):297-317. PMID 22010042
150: Stefani A, Heidbreder A, Brandauer E, et al. Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. Sleep 2018;41(6). PMID 29554362
151: Stiasny-Kolster K, Sixel-Doring F, Trenkwalder C, et al. Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. Sleep Med 2015;16(1):186-9. PMID 25534709
152: Takeuchi N, Uchimura N, Hashizume Y, et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci 2001;55(3):267-9. PMID 11422870
153: Tang WK, Hermann DM, Chen YK, et al. Brainstem infarcts predict REM sleep behavior disorder in acute ischemic stroke. BMC Neurol 2014;14:88. PMID 24758223
154: Teigen LN, Sharp RR, Hirsch JR, et al. Specialist approaches to prognostic counseling in isolated REM sleep behavior disorder. Sleep Med 2021;79:107-12. PMID 33486257
155: Teman PT, Tippmann-Peikert M, Silber MH, Slocumb NL, Auger RR. Idiopathic rapid-eye-movement sleep disorder: associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. Sleep Med 2009;10(1):60-5. PMID 18226952
156: Terzaghi M, Toscano G, Casoni F, et al. Assessment of cognitive profile as a prodromal marker of the evolution of REM sleep behavior disorder. Sleep 2019;42(8):zsz103. PMID 31013340
157: Tribl GG, Trindade MC, Bittencourt T, et al. Wilson’s disease with and without rapid eye movement sleep behavior disorder compared to healthy controls. Sleep Med 2016;17:179-85. PMID 26763676
158: Uguccioni G, Golmard JL, de Fontreaux AN, Leu-Semenescu S, Brion A, Arnulf I. Fight or flight. Dream content during sleepwalking/sleep terrors vs. rapid eye movement sleep behavior disorder. Sleep Med 2013;14(5):391-8. PMID 23601752
159: Vale TC, Fernandes do Prado LB, do Prado GF, Povoas Barsottini OG, Pedroso JL. Rapid eye movement sleep behavior disorder in paraneoplastic cerebellar degeneration: improvement with immunotherapy. Sleep 2016;39(1):117-20. PMID 26414894
160: Valencia Garcia S, Libourel PA, Lazarus M, Grassi D, Luppi PH, Fort P. Genetic inactivation of glutamate neurons in the rat sublaterodorsal tegmental nucleus recapitulates REM sleep behaviour disorder. Brain 2017;140(Pt 2):414-28. PMID 28007991
161: Videnovic A, Marlin C, Alibiglou L, et al. Increased REM sleep without atonia in Parkinson’s disease patients with freezing of gait. Neurology 2013;81(12):1030-5. PMID 23946301
162: Wallace DM, Shafazand S, Carvalho DZ, et al. Sleep-related falling out of bed in Parkinson's disease. J Clin Neurol 2012;8(1):51-7. PMID 22523513
163: Wing YK, Lam SP, Zhang J, et al. Reduced striatal dopamine transmission in REM sleep behavior disorder comorbid with depression. Neurology 2015;84(5):516-22. PMID 25568298
164: Wu YH, Lee WJ, Chen YH, Chang MH, Lin CH3. Premotor symptoms as predictors of outcome in Parkinsons disease: a case-control study. PLoS One 2016;11(8):e0161271. PMID 27533053
165: Yao C, Fereshtehnejad SM, Dawson BK, et al. Longstanding disease-free survival in idiopathic REM sleep behavior disorder: Is neurodegeneration inevitable? Parkinsonism Relat Disord 2018;54:99-102. PMID 29724601
166: Ye G, Xu X, Zhou L, Zhao A, Zhu L, Liu J. Evolution patterns of probable REM sleep behavior disorder predicts Parkinson's disease progression. NPJ Parkinsons Dis 2022;8(1):36. PMID 35383198
167: Zhang B, Hao Y, Jia F, et al. Sertraline and rapid eye movement sleep without atonia: an 8 week, open-label study of depressed patients. Prog Neuropsychophramacol Biol Psychiatry 2013;47:85-92. PMID 23994660
168: Zhang J, Lam SP, Ho CK, et al. Diagnosis of REM sleep behavior disorder by video-polysomnographic study: is one night enough. Sleep 2008;31(8):1179-85. PMID 18714790
169: Zhang W, Chen XY, Su SW, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci 2016;37(1):57-65. PMID 26255301
170: Zhou J, Zhang J, Lam SP, et al. Mortality and its risk factors in patients with rapid eye movement sleep behavior disorder. Sleep 2016;39(8):1543-50. PMID 27306273

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Stuart J McCarter MD

Dr. McCarter of the Mayo Clinic has no relevant financial relationships to disclose.
See Profile

Editor

Michael J Howell MD

Dr. Howell of the University of Minnesota has no relevant financial relationships to disclose.
See Profile

Former Authors

Mark W Mahowald MD and Michael J Howell MD

Patient Profile

Age range of presentation: 2 to 65+ years
Sex preponderance: male>female, >1:1
Heredity: heredity may be a factor
Population groups selectively affected: none
Occupation groups selectively affected: none

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Rapid eye movement sleep behavior disorder

Associated Disorders

Agrypnia excitata
Idiopathic Lewy body disease (dementia with Lewy body disease)
Multiple sclerosis
Multiple system atrophy
Narcolepsy
- Nightmare disorder
- Parkinson disease
- Parasomnia overlap disorder
- Shy-Drager syndrome
- Sleepwalking
- Spinocerebellar ataxia type 3 (Machado-Joseph disease)
- Synucleinopathies
- Voltage-gated potassium channel antibody-associated limbic encephalitis

Differential Diagnosis

confusional arousals
night terrors
delirium
nocturnal panic disorder
nocturnal seizures
- obstructive sleep apnea
- parasomnia overlap disorder
- periodic limb movement disorder
- posttraumatic stress disorder
- psychogenic dissociative states
- sleep terror
- sleep-related gastroesophageal reflux
- sleepwalking

Also Relevant

Hyposmia in neurodegenerative disorders
Nightmares
Parasomnias
Psychogenic movement disorders
Sleep and alcohol use and abuse
- Sleep and cerebral degenerative disorders
- Sleep and medical disorders
- Sleep and mental disorders
- Sleep and parkinsonism
- Spinocerebellar ataxia type 3
- Sleep terror
- Sleepwalking

Clinical Categories

Sleep Disorders

Web References

Clinical Trials

NIH: Sleep Disorders

Rapid eye movement sleep behavior disorder (RBD) …

Rapid eye movement sleep behavior disorder

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. REM Sleep Behavior Disorder Criteria (ICSD-3)

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Telehealth and cognitive behavioral therapy for insomnia (CBT-I)

NonREM parasomnias

Neurologic disorders associated with obesity

Hypersomnolence

Sleep disorders in women

Sleep, stroke, and vascular dementia

Parasomnia overlap disorder and status dissociatus

Stimulant-dependent sleep disorder

Rapid eye movement sleep behavior disorder

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. REM Sleep Behavior Disorder Criteria (ICSD-3)

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Telehealth and cognitive behavioral therapy for insomnia (CBT-I)

NonREM parasomnias

Neurologic disorders associated with obesity

Hypersomnolence

Sleep disorders in women

Sleep, stroke, and vascular dementia

Parasomnia overlap disorder and status dissociatus

Stimulant-dependent sleep disorder

This is an article preview.
Start a Free Account
to access the full version.